INTRODUCTION
C hordoma was first described by Virchow in 1857 under the name of "ecchordosis physaliphora". '7 In 1894, Ribbert defined chordoma as a malignant tumor arising from embryonic remains of the notochord. '2 The preferential localization of chordoma is in the vertebral column, from the spheno-occipital synchondrosis to the coccyx, more frequently in the sacrococcygeal regionY
The majority of chordomas are slow growing with local proliferation and high aggressiveness and infiltration of the adjacent organs and structures (Fig. 1) . Surgery is the only curative treatment 7.X.lJ.13 when adequate margins are obtained. There is a low rate of metastases for this type of tumor. 7 for a 21-month period; the second was submitted exclusively to radiation therapy, dying due to the disease after II months, and the third was treated with surgery alone and has been disease free for a 3-month period.
The patient with tumor in the retroperitoneum was submitted exclusively to chemotherapy, dying II months after admission.
From the total of 24 cases, eight (33.4%) have developed metastases in the following sites: lung-5; liver, Iymphonodus and bone-one case each. The 5-year overall survival is shown in Figure 2 . Chordoma is a rare neoplasm even in a cancer center. The present series of 24 cases represented 0.02% of all 79,917 new cancer cases seen at the A.C.CamargoHospital . Among the 1,030 cases of bone tumors in the same period, chordomas corresponded only to 2.2%.
The chordoma can arise from all axial skeleton, but various authors show that 50% begin in the sacrum, 35% in the spheno-occipital region and 15% in the vertebrae.: U . 7 .
'J
The localization out of the spine is rare.') In this series, the majority of the tumors were in the sacral region, but we must remember that before the introduction of computerized tomography, it was difficult to obtai n the diagnosis of spheno-occipital lesions.
The time elapsed between the initial symptoms and the treatment is usually very long, which is a characteristic of a slow-growing tumor. Presence of mass and sacral pain, with rectal and urinary bladder dysfunction are the main symptoms of the disease in the sacrococcygeal region.
l )
The digital rectal examination is a very important propedeutic method for diagnosis of sacral tumors.
In spheno-occipital lesions the main signs and symptoms are pain, mass-invading nasopharynx, In the 20 cases with tumor in the sacral region, the treatment and overall survival were: a) radiation therapy alone (5 cases) -5 to 50 months (mean-18.8); b) radiation therapy and surgery (4 cases) -I to 88 months (mean-27.8); c) radiation therapy, chemotherapy and surgery (4 cases) -6 to 45 months (mean-24.8); d) surgery alone (3 cases) -II to 17 months (mean-14); e) chemotherapy and surgery (I case) -27 months; f) chemotherapy and radiation therapy (I case) -31 months. Two patients did not receive any treatment due to the advanced stage of the disease.
In the 3 cases with tumors in the head and neck region (ages 10, I I and 21 years old), the first was treated with surgery and radiation therapy and has been disease free
RESULTS

MATERIALS AND METHODS
A series of 24 patients with chordomas was identified in the Hospital files , with ages ranging from 2 to 86 years (mean=34.5), 12 males and 12 females; 22 were white. The anatomical location was: sacrum-20 cases (83.4%), 8 with extension to the coccyx and 5 invading to the lumbar column; head and neck-3 cases (12.4%) in the clivus region; retroperitoneum-I case (4.2%). A summary of clinical data, treatment and follow-up is shown in Table 1 .
When ultrasonography, computerized tomography and magnetic resonance were not available, the diagnosis of tumors in the sacral region were made through digital rectal examination and barium enema. In the absence of imaging exams, the diagnosis of chordomas of other locations were very difficult due to the lack of other trustworthy methods.
QUI' therapeutic approach for chordomas is curative surgery followed by adjuvant radiation therapy and/or chemotherapy. This conduct was not always possible in our series because 13 out 24 cases were previously submitted to various types of treatment with residual or recurrent disease, and the majority of the intact cases had advanced tumors. In two cases, due to this reason, no treatment was possible.
Radiation therapy, combined or alone, was the treatment in 16 (66.7%) of the cases, being 9 (37.5%) associated with surgery and 5 (20.9%) with chemotherapy. Chemotherapy was the exclusive treatment in the case of the retroperi toneal tu mol'. m-male, f-female, RT-radiation therapy, CT-chemotherapy, act-actinomycin, cyc-cyclophosphamide, vbl-vinblastine SFU.-S fluorouracil, vin-vincristine, MTX-methotrexate, adr-adriamycin, cis-cisplatin, dti-dacarbazine, ble-bleomyciñ~~~" sometimes with obstruction of air passage and dysfunction of cranial nerves. lI The metastases rate found in our series (33.4%) is within the range described in the literature.4.1I.lJ.11I Conventional x-ray, computerized tomography and magnetic resonance are very important in the diagnosis and to plan the better treatment. In the histopathology, the presence of large cells with lobular arrangement and intracytoplasmatic mucus, called physaliphora cells, is characteristic of chordomas (Fig. 3) .
Surgery with adequate margins is the best available treatment for chordomas, but this is not always possible due to the advanced stage of the disease and difficult access 5 (Fig. 4) . The extent of curative surgery is a dilemma, because the total removal of the tumor many times implies rectal and urinary bladder impairment.
The results of radiation therapy alone are not satisfactory, however is indicated in the absence of better therapeutic options 1I.11I and the dosage varies from 70 to 80 Gy.". 16 The chemotherapy (PYB scheme -cisplatin, vinblastine, bleomycin) was used in our retroperitoneal case of chordoma and was unsuccessful. Azzarelli reported one case with complete remission with chemotherapy (PYB scheme) that allowed surgical treatment. However, this patient had local recurrence 3 months later. 2 A 50% five-year survival rate is reported by Smith in patients with sacral lesions. 14 In the Queen Elizabeth Hospital series no difference was found between patients submitted to palliative radiation therapy and those without treatment. 4 The same author reported a 5-year survival rate between 50% and 60% for cases submitted to surgery with adequate Inargins followed by radiation therapy, 25% for cases submitted to palliative radiation therapy and 15% for patients submitted to palliative surgery. 4 Keisch reported a 5-year survival rate of 100% for cases submitted to surgery with adequate margins and radiation therapy, Table 2 Five-year overall survival reported by some authors for chordomas and 68% for cases submitted only to surgery with adequate margins. lo This excellent result indicates the necessity of combined treatment and early diagnosis. The five year overall survival reported by some authors are shown in Table 2 .
The 4.2% five year survival obtained in our series is an indication of the advanced stage of the disease and recurrence after previous inadequate treatment.
Since chordomas are a slow-growing and rare tumors, multidisciplinary approach and early diagnosis are required for adequate treatment.
RESUMO
Introduc;:ao: 0 cordoma e um tumor raro e de crescimento lento, com agressividade local e localizayao preferencial na coluna vertebral. Objetivo: 0 objetivo principal deste estudo e analisar a hist6ria natural e os resultados de tratamento dos cordomas. Metodologia: Este e um estudo retrospectivo realizado entre 1953 e 1993. Material e Metodos: A idade variou de 2 a 86 anos (media=34,5). Doze pacientes eram do sexo masculino e 12 do sexo feminino. A 10calizaQaodo tumor era: regiao sacral em 20 casos, cabeya e pescoyo em 3 casos e fora da col una em um caso. Resultados: 0 tratamento, sozinho ou combinado, foi cirurgia, radioterapia e quimioterapia. A sobrevida para pacientes com les6es no sacro variou de 4 a 119 meses, desde a data dos sintomas. A sobrevida global em 5 anos foi de 4,2%. Conclusao: Cordoma e um tumor raro e de crescimento lento, com uma abordagem terapeutica cirurgica diffcil devido a sua localizayao preferencial no sacro e resultados pobres com radioterapia ou quimioterapia, principalmente em pacientes com doenya avanr;ada.
